481 related articles for article (PubMed ID: 26546432)
1. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract][Full Text] [Related]
2. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147
Lv Y; Wang T; Fan J; Zhang Z; Zhang J; Xu C; Li Y; Zhao G; He C; Meng H; Yang H; Wang Z; Liu J; Chen J; Wang L
Tumour Biol; 2017 Apr; 39(4):1010428317695927. PubMed ID: 28381172
[TBL] [Abstract][Full Text] [Related]
3. The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells.
Jiang Z; Hao Y; Ding X; Zhang Z; Liu P; Wei X; Xi J
Tumour Biol; 2016 Aug; 37(8):10383-92. PubMed ID: 26846105
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
[TBL] [Abstract][Full Text] [Related]
5. SLC34A2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells.
Zhang L; Guo X; Zhang L; Yang F; Qin L; Zhang D; Qin Y
Mol Carcinog; 2018 Mar; 57(3):440-450. PubMed ID: 29178392
[TBL] [Abstract][Full Text] [Related]
6. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
7. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
8. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
9. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
[TBL] [Abstract][Full Text] [Related]
10. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
Ma X; Zhang Y; Kang Y; Li L; Zheng W
Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
[TBL] [Abstract][Full Text] [Related]
11. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.
Zhu Y; Yu F; Jiao Y; Feng J; Tang W; Yao H; Gong C; Chen J; Su F; Zhang Y; Song E
Clin Cancer Res; 2011 Nov; 17(22):7105-15. PubMed ID: 21953503
[TBL] [Abstract][Full Text] [Related]
12. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.
Zhang ZM; Wu JF; Luo QC; Liu QF; Wu QW; Ye GD; She HQ; Li BA
Oncogene; 2016 Sep; 35(36):4787-97. PubMed ID: 26876203
[TBL] [Abstract][Full Text] [Related]
13. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
16. Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.
Zhou Q; Ye M; Lu Y; Zhang H; Chen Q; Huang S; Su S
PLoS One; 2015; 10(8):e0136694. PubMed ID: 26305906
[TBL] [Abstract][Full Text] [Related]
17. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47.
Tan W; Tang H; Jiang X; Ye F; Huang L; Shi D; Li L; Huang X; Li L; Xie X; Xie X
J Cell Mol Med; 2019 Sep; 23(9):5994-6004. PubMed ID: 31273952
[TBL] [Abstract][Full Text] [Related]
18. [Expression of breast cancer resistance protein and p-glycoprotein in residual breast cancer tissue after chemotherapy and its correlation with cancer stem cells].
Qu HB; Fan YM; Han ML; Luo HJ; Xie J; Liu H; Liu H; Wu CY; Tang WX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):171-6. PubMed ID: 23643006
[TBL] [Abstract][Full Text] [Related]
19. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
20. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]